Exai Bio today announced new data from a 3,300 subject study demonstrating that its novel RNA- and AI-based platform can detect multiple cancer types at the earliest stages using a single, standard blood sample.
Exai Bio's core technology is founded on UCSF research done by Hani Goodarzi, PhD.
More
